Search Results - "Clamon, Gerald"

O2⋅− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate by Schoenfeld, Joshua D., Sibenaller, Zita A., Mapuskar, Kranti A., Wagner, Brett A., Cramer-Morales, Kimberly L., Furqan, Muhammad, Sandhu, Sonia, Carlisle, Thomas L., Smith, Mark C., Abu Hejleh, Taher, Berg, Daniel J., Zhang, Jun, Keech, John, Parekh, Kalpaj R., Bhatia, Sudershan, Monga, Varun, Bodeker, Kellie L., Ahmann, Logan, Vollstedt, Sandy, Brown, Heather, Shanahan Kauffman, Erin P., Schall, Mary E., Hohl, Ray J., Clamon, Gerald H., Greenlee, Jeremy D., Howard, Matthew A., Schultz, Michael K., Smith, Brian J., Riley, Dennis P., Domann, Frederick E., Cullen, Joseph J., Buettner, Garry R., Buatti, John M., Spitz, Douglas R., Allen, Bryan G.

“…Pharmacological ascorbate has been proposed as a potential anti-cancer agent when combined with radiation and chemotherapy. The anti-cancer effects of…”
Get full text

Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer by AUPERIN, Anne, LE PECHOUX, Cecile, YAMANAKA, Takeharu, BOZONNAT, Marie-Cecile, UITTERHOEVE, Apollonia, XIAOFEI WANG, STEWART, Lesley, ARRIAGADA, Rodrigo, BURDETT, Sarah, PIGNON, Jean-Pierre, ROLLAND, Estelle, CURRAN, Walter J, FURUSE, Kiyoyuki, FOURNEL, Pierre, BELDERBOS, Jose, CLAMON, Gerald, CUNEYT ULUTIN, Hakki, PAULUS, Rebecca

“…The previous individual patient data meta-analyses of chemotherapy in locally advanced non-small-cell lung cancer (NSCLC) showed that adding sequential or…”
Get full text

Consuming a Ketogenic Diet while Receiving Radiation and Chemotherapy for Locally Advanced Lung Cancer and Pancreatic Cancer: The University of Iowa Experience of Two Phase 1 Clinical Trials by Zahra, Amir, Fath, Melissa A., Opat, Emyleigh, Mapuskar, Kranti A., Bhatia, Sudershan K., Ma, Daniel C., III, Samuel N. Rodman, Snyders, Travis P., Chenard, Catherine A., Eichenberger-Gilmore, Julie M., Bodeker, Kellie L., Ahmann, Logan, Smith, Brian J., Vollstedt, Sandy A., Brown, Heather A., Hejleh, Taher Abu, Clamon, Gerald H., Berg, Daniel J., Szweda, Luke I., Spitz, Douglas R., Buatti, John M., Allen, Bryan G.

“…Ketogenic diets are low in carbohydrates and high in fat, which forces cells to rely more heavily upon mitochondrial oxidation of fatty acids for energy…”
Get full text

Inflammation as a Therapeutic Target in Cancer Cachexia by Clamon, Gerald, Byrne, Margaret M, Talbert, Erin E

“…Cachexia is a common complication of cancer and is associated with poor quality of life and a decrease in survival. Many patients with cancer cachexia suffer…”
Get full text

Financial impact of oral chemotherapy wastage on society and the patient by Monga, Varun, Meyer, Chenise, Vakiner, Brandon, Clamon, Gerald

“…Background Targeted oral agents are now increasingly being utilized in cancer treatment, but are expensive. Changing the dose of these medications due to…”
Get full text

Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non–Small-Cell Lung Cancer: ECOG 5597 by KARP, Daniel D, LEE, Sandra J, OKAWARA, Gordon, MARKS, Randolph, FRECHETTE, Eric, MCCASKILL-STEVENS, Worta, LIPPMAN, Scott M, RUCKDESCHEL, John, KHURI, Fadlo R, KELLER, Steven M, WRIGHT, Gail Shaw, AISNER, Seena, BELINSKY, Steven Alan, JOHNSON, David H, JOHNSTON, Michael R, GOODMAN, Gary, CLAMON, Gerald

“…Selenium has been reported to have chemopreventive benefits in lung cancer. We conducted a double-blind, placebo-controlled trial to evaluate the incidence of…”
Get full text

Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer by Byrne, Margaret M, Sutamtewagul, Grerk, Zeitler, William, Mott, Sarah L, Zamba, Gideon K D, Kojadinovic, Arsenije, Zhang, Jun, Abu-Hejleh, Taher, Clamon, Gerald, Furqan, Muhammad

“…Patients with small cell lung cancer (SCLC) often respond to first-line chemoimmunotherapy. However, relapse is inevitable and is associated with a poor…”
Get full text

A Phase I Study of Apolizumab, an Anti-HLA-DR ß-chain Monoclonal Antibody, in Patients With Solid Tumor Malignancies by Fracasso, Paula M., Goodner, Sherry A., Wildi, Jonathan D., Naughton, Michael J., Linette, Gerald P., Govindan, Ramaswamy, Tan, Benjamin R., Blum, Kristie A., Jones, Gary J., Pearce, Tillman E., Levitt, Daniel J., Clamon, Gerald H.

“…Human leukocyte antigen (HLA)-DR, a member of the major histocompatibility complex class II antigen family, is a target for antibody-based therapeutics…”
Get full text

SBRT to adrenal metastases provides high local control with minimal toxicity by Plichta, Kristin, MD, PhD, Camden, Nathan, BS, Furqan, Muhammed, MD, Hejleh, Taher Abu, MBBS, Clamon, Gerald H., MD, Zhang, Jun, MD, PhD, Flynn, Ryan T., PhD, Bhatia, Sudershan K., MD, PhD, Smith, Mark C., MD, Buatti, John M., MD, Allen, Bryan G., MD, PhD

“…Abstract Purpose The adrenal glands are a common site of metastases because of their rich blood supply. Previously, adrenal metastases were treated with…”
Get full text

Comparing high‐dose cisplatin with cisplatin‐based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC) by Furqan, Muhammad, Snyders, Travis P., Saqlain, Mohammed U., Mott, Sarah L., Laux, Douglas, Snow, Anthony, Anderson, Carryn M., Watkins, John M., Clamon, Gerald H.

“…Background High‐dose cisplatin (Cis) is a preferred systemic agent for concurrent chemoradiation (CRT) in locally advanced head and neck squamous cell cancer…”
Get full text

Germline mutations predisposing to non-small cell lung cancer by Clamon, Gerald H., Bossler, Aaron D., Hejleh, Taher Abu, Furqan, Muhammad

“…Lung cancer in multiple first degree relatives had previously been attributed to smoking and to inherited enzymes associated with increased activation of…”
Get full text

O2⋅− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate by Schoenfeld, Joshua D., Sibenaller, Zita A., Mapuskar, Kranti A., Wagner, Brett A., Cramer-Morales, Kimberly L., Furqan, Muhammad, Sandhu, Sonia, Carlisle, Thomas L., Smith, Mark C., Abu Hejleh, Taher, Berg, Daniel J., Zhang, Jun, Keech, John, Parekh, Kalpaj R., Bhatia, Sudershan, Monga, Varun, Bodeker, Kellie L., Ahmann, Logan, Vollstedt, Sandy, Brown, Heather, Kauffman, Erin P. Shanahan, Schall, Mary E., Hohl, Ray J., Clamon, Gerald H., Greenlee, Jeremy D., Howard, Matthew A., Schultz, Michael K., Smith, Brian J., Riley, Dennis P., Domann, Frederick E., Cullen, Joseph J., Buettner, Garry R., Buatti, John M., Spitz, Douglas R., Allen, Bryan G.

Get full text

O 2 ⋅- and H 2 O 2 -Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate by Schoenfeld, Joshua D, Sibenaller, Zita A, Mapuskar, Kranti A, Wagner, Brett A, Cramer-Morales, Kimberly L, Furqan, Muhammad, Sandhu, Sonia, Carlisle, Thomas L, Smith, Mark C, Abu Hejleh, Taher, Berg, Daniel J, Zhang, Jun, Keech, John, Parekh, Kalpaj R, Bhatia, Sudershan, Monga, Varun, Bodeker, Kellie L, Ahmann, Logan, Vollstedt, Sandy, Brown, Heather, Shanahan Kauffman, Erin P, Schall, Mary E, Hohl, Ray J, Clamon, Gerald H, Greenlee, Jeremy D, Howard, Matthew A, Schultz, Michael K, Smith, Brian J, Riley, Dennis P, Domann, Frederick E, Cullen, Joseph J, Buettner, Garry R, Buatti, John M, Spitz, Douglas R, Allen, Bryan G

“…Pharmacological ascorbate has been proposed as a potential anti-cancer agent when combined with radiation and chemotherapy. The anti-cancer effects of…”
Get full text

Rapidly Progressing Primary Extrahepatic Bile Duct Signet-Ring Cell Carcinoma in a Caucasian Woman by Welsh, Jessemae L., Jaber, Omar, Ivanovic, Marina, Johlin, Frederick C., El Abiad, Rami G., Clamon, Gerald H., Smith, Mark C., Chan, Carlos H. F.

Get full text

Is Planned Neck Dissection Necessary for Head and Neck Cancer After Intensity-Modulated Radiotherapy? by Yao, Min, M.D., Ph.D, Hoffman, Henry T., M.D, Chang, Kristi, M.D, Funk, Gerry F., M.D, Smith, Russell B., M.D, Tan, Huaming, M.S, Clamon, Gerald H., M.D, Dornfeld, Ken, M.D., Ph.D, Buatti, John M., M.D

“…Purpose: The objective of this study was to determine regional control of local regional advanced head and neck squamous cell carcinoma (HNSCC) treated with…”
Get full text

Beta blockade as adjunctive breast cancer therapy: A review by Phadke, Sneha, Clamon, Gerald

“…Pre-clinical data has shown that beta adrenergic stimulation can affect the development and progression of many types of cancer. The use of beta blockers as an…”
Get full text

Differences in Clinical Trial Patient Attributes and Outcomes According to Enrollment Setting by LAMONT, Elizabeth B, LANDRUM, Mary Beth, MILLER, Antonius A, CLAMON, Gerald H, ELIAS, Anthony D, MCCLAY, Edward F, VOKES, Everett E, MCNEIL, Barbara J, KEATING, Nancy L, ARCHER, Laura, LAN LAN, STRAUSS, Gary M, LILENBAUM, Rogerio, NIELL, Harvey B, HERBERT MAURER, L, KOSTY, Michael P

“…During the last 25 years, National Cancer Institute (NCI) cooperative trial groups have extended trial networks from academic centers to include certain…”
Get full text

Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies by HOLSTEIN, Sarah A, KNAPP, Howard R, CLAMON, Gerald H, MURRY, Daryl J, HOHL, Raymond J

“…Lovastatin, an inhibitor of the rate-limiting enzyme in the cholesterol biosynthetic pathway, hydroxymethylglutaryl coenzyme A reductase, has shown interesting…”
Get full text

Radiosensitization With Carboplatin for Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: A Phase III Trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group by CLAMON, G, HERNDON, J, COOPER, R, CHANG, A. Y, ROSENMAN, J, GREEN, M. R

“…To determine whether the administration of carboplatin concurrently with radiation treatment improves survival in patients with inoperable stage III…”
Get full text

Changing failure patterns in oropharyngeal squamous cell carcinoma treated with intensity modulated radiotherapy and implications for future research by Yao, Min, Nguyen, Thanh, Buatti, John M, Dornfeld, Kenneth J, Tan, Huaming, Wacha, Judith, Bayouth, John E, Clamon, Gerald H, Funk, Gerry F, Smith, Russell B, Chang, Kristi, Hoffman, Henry T

“…Review the University of Iowa experience with intensity modulated radiation treatment (IMRT) in oropharyngeal squamous cell carcinoma. From January 2000 to…”
Get full text